ofloxacin has been researched along with Anthrax in 13 studies
Ofloxacin: A synthetic fluoroquinolone antibacterial agent that inhibits the supercoiling activity of bacterial DNA GYRASE, halting DNA REPLICATION.
9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid : An oxazinoquinoline that is 2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinolin-7-one substituted by methyl, carboxy, fluoro, and 4-methylpiperazin-1-yl groups at positions 3, 6, 9, and 10, respectively.
ofloxacin : A racemate comprising equimolar amounts of levofloxacin and dextrofloxacin. It is a synthetic fluoroquinolone antibacterial agent which inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication.
Anthrax: An acute infection caused by the spore-forming bacteria BACILLUS ANTHRACIS. It commonly affects hoofed animals such as sheep and goats. Infection in humans often involves the skin (cutaneous anthrax), the lungs (inhalation anthrax), or the gastrointestinal tract. Anthrax is not contagious and can be treated with antibiotics.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Levofloxacin was recently (May 2008) approved by the U." | 6.75 | Pharmacometrics-based dose selection of levofloxacin as a treatment for postexposure inhalational anthrax in children. ( Chien, S; Li, F; Nandy, P; Noel, GJ; Tornoe, CW, 2010) |
| "Ciprofloxacin was administered at 16 mg/kg twice a day." | 5.33 | Pharmacokinetic considerations and efficacy of levofloxacin in an inhalational anthrax (postexposure) rhesus monkey model. ( Barnewall, R; Bush, K; Chien, S; Drusano, GL; Estep, J; Hemeryck, A; Kao, LM; Kelley, MF; Minton, N; Olson, PH; Thalacker, FW, 2006) |
| " The objective of this study was to identify a levofloxacin treatment regimen that will serve as an effective therapy for Bacillus anthracis infections and postexposure prophylaxis." | 3.73 | Effective antimicrobial regimens for use in humans for therapy of Bacillus anthracis infections and postexposure prophylaxis. ( Basset, J; Bush, K; Byrne, WR; Deziel, MR; Drusano, GL; Heine, H; Kao, M; Kelly, M; Louie, A; Miller, L, 2005) |
| "Levofloxacin was recently (May 2008) approved by the U." | 2.75 | Pharmacometrics-based dose selection of levofloxacin as a treatment for postexposure inhalational anthrax in children. ( Chien, S; Li, F; Nandy, P; Noel, GJ; Tornoe, CW, 2010) |
| "To date, anthrax is treatable if antibiotics are administered promptly and continued for 60 days." | 2.53 | Alternative pre-approved and novel therapies for the treatment of anthrax. ( Head, BM; Meyers, AF; Rubinstein, E, 2016) |
| "Levofloxacin was administered daily beginning at 6 to 12 h postexposure for 7 treatments." | 1.38 | Recombinant protective antigen anthrax vaccine improves survival when administered as a postexposure prophylaxis countermeasure with antibiotic in the New Zealand white rabbit model of inhalation anthrax. ( Bourdage, JS; Duchars, M; Fuerst, TR; Fusco, PC; Leffel, EK; Williamson, ED, 2012) |
| "Ciprofloxacin was administered at 16 mg/kg twice a day." | 1.33 | Pharmacokinetic considerations and efficacy of levofloxacin in an inhalational anthrax (postexposure) rhesus monkey model. ( Barnewall, R; Bush, K; Chien, S; Drusano, GL; Estep, J; Hemeryck, A; Kao, LM; Kelley, MF; Minton, N; Olson, PH; Thalacker, FW, 2006) |
| "Levofloxacin was bactericidal at 1 x MIC after 24 h and at 4 x MIC after 12 h, and gatifloxacin was bactericidal at 2 x MIC after 24 h and at 8 x MIC after 12 h." | 1.31 | Bactericidal activity of levofloxacin, gatifloxacin, penicillin, meropenem and rokitamycin against Bacillus anthracis clinical isolates. ( De Vecchi, E; Drago, L; Gismondo, MR; Lombardi, A; Nicola, L; Valli, M, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (53.85) | 29.6817 |
| 2010's | 6 (46.15) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Head, BM | 1 |
| Rubinstein, E | 1 |
| Meyers, AF | 1 |
| Li, F | 1 |
| Nandy, P | 1 |
| Chien, S | 2 |
| Noel, GJ | 1 |
| Tornoe, CW | 1 |
| Yee, SB | 1 |
| Hatkin, JM | 1 |
| Dyer, DN | 1 |
| Orr, SA | 1 |
| Pitt, ML | 2 |
| Weiss, S | 1 |
| Kobiler, D | 1 |
| Levy, H | 1 |
| Pass, A | 1 |
| Ophir, Y | 1 |
| Rothschild, N | 1 |
| Tal, A | 1 |
| Schlomovitz, J | 1 |
| Altboum, Z | 1 |
| Leffel, EK | 1 |
| Bourdage, JS | 1 |
| Williamson, ED | 1 |
| Duchars, M | 1 |
| Fuerst, TR | 1 |
| Fusco, PC | 1 |
| Corey, A | 1 |
| Migone, TS | 1 |
| Bolmer, S | 1 |
| Fiscella, M | 1 |
| Ward, C | 1 |
| Chen, C | 1 |
| Meister, G | 1 |
| Drago, L | 1 |
| De Vecchi, E | 1 |
| Lombardi, A | 1 |
| Nicola, L | 1 |
| Valli, M | 1 |
| Gismondo, MR | 1 |
| Jones, JW | 1 |
| Kiefe, CI | 1 |
| Bossi, P | 1 |
| Bricaire, F | 1 |
| Esel, D | 1 |
| Doganay, M | 1 |
| Sumerkan, B | 1 |
| Deziel, MR | 1 |
| Heine, H | 1 |
| Louie, A | 1 |
| Kao, M | 1 |
| Byrne, WR | 2 |
| Basset, J | 1 |
| Miller, L | 2 |
| Bush, K | 2 |
| Kelly, M | 1 |
| Drusano, GL | 2 |
| Kao, LM | 1 |
| Barnewall, R | 1 |
| Estep, J | 1 |
| Thalacker, FW | 1 |
| Olson, PH | 1 |
| Minton, N | 1 |
| Hemeryck, A | 1 |
| Kelley, MF | 1 |
| Heine, HS | 1 |
| Bassett, J | 1 |
| Hartings, JM | 1 |
| Ivins, BE | 1 |
| Fritz, D | 1 |
| Norris, SL | 1 |
2 reviews available for ofloxacin and Anthrax
| Article | Year |
|---|---|
Alternative pre-approved and novel therapies for the treatment of anthrax.
Topics: Alpha-Globulins; Anthrax; Anti-Bacterial Agents; Antibiotics, Antineoplastic; Antibodies, Monoclonal | 2016 |
[Anthrax in the era of biowarfare].
Topics: Adult; Amoxicillin; Anthrax; Anti-Bacterial Agents; Anti-Infective Agents; Biological Warfare; Biote | 2003 |
1 trial available for ofloxacin and Anthrax
| Article | Year |
|---|---|
Pharmacometrics-based dose selection of levofloxacin as a treatment for postexposure inhalational anthrax in children.
Topics: Adolescent; Aging; Anthrax; Anti-Bacterial Agents; Area Under Curve; Biological Availability; Body W | 2010 |
10 other studies available for ofloxacin and Anthrax
| Article | Year |
|---|---|
Aerosolized Bacillus anthracis infection in New Zealand white rabbits: natural history and intravenous levofloxacin treatment.
Topics: Aerosols; Animals; Anthrax; Anti-Bacterial Agents; Antigens, Bacterial; Bacillus anthracis; Bacterem | 2010 |
Antibiotics cure anthrax in animal models.
Topics: Animals; Anthrax; Anthrax Vaccines; Anti-Bacterial Agents; Antigens, Bacterial; Bacillus anthracis; | 2011 |
Recombinant protective antigen anthrax vaccine improves survival when administered as a postexposure prophylaxis countermeasure with antibiotic in the New Zealand white rabbit model of inhalation anthrax.
Topics: Animals; Anthrax; Anthrax Vaccines; Anti-Bacterial Agents; Antibiotic Prophylaxis; Antigens, Bacteri | 2012 |
Bacillus anthracis protective antigen kinetics in inhalation spore-challenged untreated or levofloxacin/ raxibacumab-treated New Zealand white rabbits.
Topics: Adjuvants, Immunologic; Administration, Inhalation; Animals; Anthrax; Anthrax Vaccines; Anti-Bacteri | 2013 |
Bactericidal activity of levofloxacin, gatifloxacin, penicillin, meropenem and rokitamycin against Bacillus anthracis clinical isolates.
Topics: Anthrax; Anti-Bacterial Agents; Anti-Infective Agents; Bacillus anthracis; Fluoroquinolones; Gatiflo | 2002 |
Anthrax attacks and practice patterns: a learning opportunity for health care systems.
Topics: Acute Disease; Alabama; Ambulatory Care Facilities; Anthrax; Antibiotic Prophylaxis; Bioterrorism; C | 2002 |
Antimicrobial susceptibilities of 40 isolates of Bacillus anthracis isolated in Turkey.
Topics: Anthrax; Anti-Bacterial Agents; Bacillus anthracis; Ciprofloxacin; Doxycycline; Drug Resistance, Bac | 2003 |
Effective antimicrobial regimens for use in humans for therapy of Bacillus anthracis infections and postexposure prophylaxis.
Topics: Animals; Anthrax; Anti-Infective Agents; Bacillus anthracis; Humans; Levofloxacin; Macaca mulatta; M | 2005 |
Pharmacokinetic considerations and efficacy of levofloxacin in an inhalational anthrax (postexposure) rhesus monkey model.
Topics: Aerosols; Animals; Anthrax; Anti-Bacterial Agents; Area Under Curve; Bacillus anthracis; Computer Si | 2006 |
Determination of antibiotic efficacy against Bacillus anthracis in a mouse aerosol challenge model.
Topics: Administration, Inhalation; Aerosols; Animals; Anthrax; Anti-Bacterial Agents; Antibiotic Prophylaxi | 2007 |